At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PROK ProKidney Corp.
Trading 10-22 12:05:59 EDT
1.45
+0.01
+0.70%
High1.48Low1.42Vol217.43K
Open1.46D1 Closing1.44Amplitude3.82%
Mkt Cap438.40MTradable Cap268.27MTotal Shares302.32M
T/O317.04KT/O Rate0.12%Tradable Shares185.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ProKidney Hosts KOL Event to Review Rilparencel Mechanism of Action Data
Reuters  ·  10-22 20:45
ProKidney Hosts KOL Event to Review Rilparencel Mechanism of Action Data
ProKidney to Host Virtual Kol Event to Recap Mechanism of Action Data Presented at Asn Kidney Week and Provide a Corporate Update
THOMSON REUTERS  ·  10-22 20:45
ProKidney to Host Virtual Kol Event to Recap Mechanism of Action Data Presented at Asn Kidney Week and Provide a Corporate Update
ProKidney Pooled Phase 2 Analysis Indicates Kidney Function Stabilization in Advanced CKD Patients
Reuters  ·  10-22 20:11
ProKidney Pooled Phase 2 Analysis Indicates Kidney Function Stabilization in Advanced CKD Patients
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)
TIPRANKS  ·  10-12
Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)
ProKidney Posts Pooled Phase 2 Data Showing Rilparencel Stabilizes Kidney Function in Advanced CKD with Diabetes
Reuters  ·  10-02
ProKidney Posts Pooled Phase 2 Data Showing Rilparencel Stabilizes Kidney Function in Advanced CKD with Diabetes
ProKidney Director Brian JG Pereira Sells USD 1.06 Million in Common Shares
Reuters  ·  08-21
ProKidney Director Brian JG Pereira Sells USD 1.06 Million in Common Shares
Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes
Reuters  ·  08-14
Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)
TIPRANKS  ·  08-13
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
Reuters  ·  08-13
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
MaxCyte Q2 Revenue Beats Estimates
Reuters  ·  08-13
MaxCyte Q2 Revenue Beats Estimates
Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition
Reuters  ·  08-13
Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Reuters  ·  08-12
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change
Reuters  ·  08-12
Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change
Humacyte Q2 Net Loss Widens on Inventory, Production Costs
Reuters  ·  08-12
Humacyte Q2 Net Loss Widens on Inventory, Production Costs
Legend Biotech Q2 Revenue Beats Estimates on Commercial Expansion
Reuters  ·  08-11
Legend Biotech Q2 Revenue Beats Estimates on Commercial Expansion
Vera Therapeutics Q2 Loss Widens Less than Expected
Reuters  ·  08-11
Vera Therapeutics Q2 Loss Widens Less than Expected
Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029
Reuters  ·  08-11
Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029
ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate
Benzinga Earnings  ·  08-11
ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate
Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise
Reuters  ·  08-11
Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise
ProKidney Q2 Operating Income USD -48.373 Million
Reuters  ·  08-11
ProKidney Q2 Operating Income USD -48.373 Million

Introduction

Company Name.
ProKidney Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Issue price:
--